Is a
Clinical Study attributes
NCT Number
Health Conditions in Trial
Trial Recruitment Size
150
Trial Sponsor
Clinical Trial Start Date
September 15, 2021
0Primary Completion Date
November 15, 2022
0Study Completion Date
December 15, 2022
0Clinical Trial Study Type
Interventional0
Interventional Trial Purpose
Treatment0
Intervention Type
Drug0
Intervention Name
PTX-0220
Interventional Trial Phase
Phase 20
Participating Facility
Official Name
A Multicenter, Phase 2, Open-Label Study Evaluating The Safety And Efficacy of Sirolimus 3.9% Topical Gel (PTX-022) In The Treatment of Microcystic Lymphatic Malformations0
Last Updated
August 29, 2022
0Allocation Type
NA0
Intervention Model
Single Group Assignment0
Masking Type
None (Open Label)0
Study summary
This study evaluates the safety and efficacy of PTX-022 (sirolimus) Topical Gel 3.9% w/w in the treatment of Microcystic Lymphatic Malformations. The participant will receive 3 months of PTX-022 treatment by the end of the study.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
